Global Biologics Drug Development Market

Global Biologics Drug Development Market: Focus on Facility, Service, Product Type, Country Analysis, and Market Dynamics - Analysis and Forecast, 2018-2027

The global biologics drug development market was estimated at $2.79 billion in 2017 and is expected to grow over $8.46 billion by 2027.

SKU: BH037B
Published Year: 2018
PLEASE SELECT A LICENSE TYPE
 
 
 

The pharmaceutical industry is a multibillion market consisting of innovator drugs and generics. The pharmaceutical market consists of companies involved in the research, development, manufacturing, and commercialization of drugs for human and animal use. The evolving healthcare needs across the world has led to the rise of novel medication for the treatment of various chronic diseases. Biologics is one such type of medication with proven efficacy and safety.

Biologics are defined as pharmaceutical products obtained from living cells or microorganisms. These are complex and large molecules consisting of proteins, peptides, nucleic acids, sugars, and cellular structures or a combination of these. The pharmaceutical industry is shifting toward biologic drug products due to their advantages over small molecule such as minimal toxicity and safety issues, high target specificity, and better understood mechanism of action. These factors prompt increased interest in the biologics; hence, there is a higher trend toward their discovery and development process.

The biologics drug development involves different types of services for the development of biologics as well as facility for their manufacture. The market can be segmented based on facility into in-house, outsource, and PharmaExcess. Based on services the market can be segmented into clinical manufacturing, formulation development, bioassay development, and analytical services. Based on the product class, monoclonal antibody is anticipated to be the major contributor to the market. However, the fastest growing segment is expected to be growth factors market. Geographically, the market is segmented into four regions namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.

The purpose of the study is to gain a holistic view of the biologics drug development market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of the report is centered upon conducting a detailed study of the solutions allied with the biologics drug development market. The market has been segmented into ‘product class’, ‘facility’, ‘services’, and ‘geographical regions’. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges, and opportunities in the global biologics drug development market and their case studies?
•    What were the market shares of the leading segments and sub-segments of the global biologics drug discovery market in 2017, and what will be the shares in 2027?
•    How will each segment of the global biologics drug development market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2027?
•    What are the influencing factors that may affect the market share of the key players?
•    How will the industry evolve during the forecast period between 2017 and 2027?
•    What are the key developmental strategies implemented by the key players to stand out in this market?
•    What will be the growth rate of the PharmaExcess segment during the forecast period?
•    Who are the key outsourced manufacturers of the biologics drug development market?
•    How the market has been segmented on the basis of services? Which service is highly adopted in the biologics drug development process?
•    Which geographical location will contribute to the highest revenue generation of the biologics drug development market?

The key players of the market include Abbvie, Inc., Allergan Plc, Boehringer Ingelheim International GmbH, Charles River Laboratories, Catalent Inc., Lonza Group, MabPlex Inc., Samsung Biologics, and Amgen, Inc., among others.

   Executive Summary
   1    Market Overview
         1.1    Biologics Drug Development
         1.2    Biologics Drug Development: Key Trends
         1.3    Integrated Discovery, Development, and commercialization of Biologics
         1.4    Clinical Developmental Stages of Biologics
         1.5    Manufacturing Stages of Biologics
         1.6    Process Development
         1.7    Bio Manufacturing Process
         1.8    Formulation Development
         1.9    Biologics In-House Drug Development Market
                  1.9.1    North America
                  1.9.2    Europe
                  1.9.3    Asia-Pacific
        1.10   Biologics Outsourcing  Drug Development Market
                  1.10.1    North America
                  1.10.2    Europe
                  1.10.3    Asia-Pacific
        1.11   Biologics Drug Development Cost
 
   2    Market Dynamics
         2.1    Market Drivers
         2.2    Market Restraints
         2.3    Market Opportunities
 
   3    Competitive Landscape
         3.1    Key Developmental Strategies
                  3.1.1    Acquisitions
                  3.1.2    Agreements, Partnership, Collaboration and Joint Ventures
                  3.1.3    Approvals
                  3.1.4.   Clinical Study
                  3.1.5    Business Expansion
                  3.1.6    Product Launch
                  3.1.7    Awards
         3.2    Porter’s Five Forces Analysis
 
   4    Biologics Drug Development Market, (by Class)
         4.1    Overview
                  4.1.1    Monoclonal Antibodies (mAbs)
                  4.1.2    Hormones
                  4.1.3    Growth Factors
                  4.1.4    Cytokines and Fusion Proteins
                  4.1.5    Therapeutic Enzymes
                  4.1.6    Blood Factors and Anticoagulants
                  4.1.7    Vaccines
 
   5    Biologics Drug Development Market, (by Facility)
         5.1    Overview
                   5.1.1    In-House
                   5.1.2    Outsource
                   5.1.3    Pharma Excess
 
   6    Biologics Drug Development Market, (by Services)
         6.1    Overview
                  6.1.1    Clinical Manufacturing
                              6.1.1.1    Cell Bank Preparation and Cell Line Development
                              6.1.1.2    Cell Culture Upstream Development
                              6.1.1.3    Purification Downstream Development
                  6.1.2    Formulation Development
                  6.1.3    Bioassay Development
                  6.1.4    Analytical Services
 
   7    Biologics Drug Development Market, (by Region)
         7.1    Global Scenario
         7.2    North America
                  7.2.1    The U.S.
                  7.2.2    Canada
         7.3    Europe
                  7.3.1    The U.K.
                  7.3.2    Germany
                  7.3.3    France
                  7.3.4    Switzerland
                  7.3.5    Rest-of-Europe
         7.4    Asia Pacific
                  7.4.1    Japan
                  7.4.2    China
                  7.4.3    South Korea
                  7.4.4    India
                  7.4.5    Rest-of-Asia-Pacific
         7.5    Rest-of-the-World (RoW)
 
   8    Company Profiles
         8.1    AbbVie Inc.
                  8.1.1    Abbvie Inc. : Overview
                  8.1.2    Abbvie Inc.: Overall Product Portfolio
                              8.1.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.1.3    Financials
                              8.1.3.1    Financial Summary
                  8.1.4    SWOT Analysis
         8.2    Allergan
                  8.2.1    Allergan Plc: Overview
                  8.2.2    Allergan Plc: Overall Product Portfolio
                              8.2.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.2.3    Financials
                              8.2.3.1    Financial Summary
                  8.2.4    SWOT Analysis
         8.3    Amgen, Inc.
                  8.3.1    Amgen, Inc.: Overview
                  8.3.2    Amgen, Inc.: Overall Product Portfolio
                              8.3.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.3.3    Financials
                              8.3.3.1    Financial Summary
                  8.3.4    SWOT Analysis
         8.4    Boehringer Ingelheim International GmbH
                  8.4.1    Boehringer Ingelheim International GmbH: Overview
                  8.4.2    Boehringer Ingelheim International GmbH: Overall Product Portfolio
                              8.4.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.4.3    Financials
                              8.4.3.1    Financial Summary
                  8.4.4    SWOT Analysis
         8.5    Catalent Inc.
                  8.5.1    Catalent Inc.: Overview
                  8.5.2    Catalent Inc.: Overall Product Portfolio
                              8.5.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.5.3    Financials
                              8.5.3.1    Financial Summary
                  8.5.4    SWOT Analysis
         8.6    Charles River Laboratories
                  8.6.1    Charles River Laboratories: Overview
                  8.6.2    Charles River Laboratories: Overall Product Portfolio
                              8.6.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.6.3    Financials
                              8.6.3.1    Financial Summary
                  8.6.4    SWOT Analysis
         8.7    FUJIFILM Diosynth Biotechnologies U.S.A., Inc
                  8.7.1    FUJIFILM Diosynth Biotechnologies U.S.A., Inc: Overview
                  8.7.2    FUJIFILM Holdings Corporation: Parent Company Overview
                  8.7.3    FUJIFILM Holdings Corporation: Overall Product Portfolio
                              8.7.3.1    Product Offerings for Global Biologics Drug Development Market
                  8.7.4    Financials
                              8.7.4.1    Financial Summary
                  8.7.5    SWOT Analysis
         8.8    KBI  Biopharma
                  8.8.1    KBI Biopharma: Overview
                  8.8.2    Corporate Summary
                  8.8.3    Product Offerings for Global Biologics Drug Development Market
                  8.8.4    SWOT Analysis
         8.9    Lonza
                  8.9.1    Lonza: Overview
                  8.9.2    Lonza: Overall Product Portfolio
                              8.9.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.9.3    Financials
                              8.9.3.1    Financial Summary
                  8.9.4    SWOT Analysis
        8.10   MabPlex Inc.
                  8.10.1    MabPlex Inc.: Overview
                  8.10.2    Corporate Summary
                  8.10.3    Product Offerings for Global Biologics Drug Development Market
                  8.10.4    SWOT Analysis
        8.11   Patheon
                  8.11.1    Patheon: Overview
                  8.11.2    Thermo Fisher Scientific, Inc.: Parent Company Overview
                  8.11.3    Thermo Fisher Scientific, Inc.: Overall Product Portfolio
                                8.11.3.1    Product Offerings for Global Biologics Drug Development Market
                  8.11.4    Thermo Fisher Scientific: Financials
                                8.11.4.1    Financial Summary
                  8.11.5    SWOT Analysis
        8.12   Samsung BioLogics
                  8.12.1    Samsung BioLogics: Overview
                  8.12.2    Samsung BioLogics: Overall Product Portfolio
                                8.12.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.12.3    Financials
                                8.12.3.1    Financial Summary
                  8.12.4    SWOT Analysis
       8.13   SANOFI
                  8.13.1    SANOFI: Overview
                  8.13.2    SANOFI: Overall Product Portfolio
                                8.13.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.13.3    Financials
                                8.13.3.1    Financial Summary
                  8.13.4    SWOT Analysis
        8.14   Singota Solutions
                  8.14.1    Singota Solutions: Overview
                  8.14.2    Corporate Summary
                  8.14.3    Product Offerings for Global Biologics Drug Development Market
                  8.14.4    SWOT Analysis
        8.15   WuXi Biologics
                  8.15.1    WuXi Biologics: Overview
                  8.15.2    WuXi Biologics: Overall Product Portfolio
                                8.15.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.15.3    Financials
                                8.15.3.1    Financial Summary
                  8.15.4    SWOT Analysis
 
   9    Consumer Perception(Pharmaceutical Companies) on Clinical Manufacturing of Biologics Drugs
 
   10    Report Scope and Methodology
           10.1    Scope of the Report
           10.2    Global Biologics Drug Development Market Segmentation
           10.3    Research Methodology
                      10.3.1    Data Triangulation
                      10.3.2    Key Data Points from Secondary Sources
                      10.3.3    Key Data Points from Primary Sources
                      10.3.4    Top-Down Approach (Segmental Analysis)
                      10.3.5    Bottom-Up Approach (Segmental Analysis)
           10.4    Assumptions and Limitations
           10.5    Data and Prediction Modelling
 

List of Tables

1    Total Regional Geriatric Population (by Region %), 2015 and 2030
2    Drug Approvals by FDA
3    Impact of Market Drivers
4    Impact of Market Restraints
5    Key Market Players in Biologics Drug Development
6    Biologics Drug Development Cost Per Molecule ($Million)
7    Biosimilars Drug Development Cost Per Molecule ($Million
8    Manufacturing Cost Per Gram ($/gm)
9    Global Volume Production by Company Type ($Million)
10    Impact of Market Drivers
11    Impact of Market Restraints
12    R&D Expenditure of a Few Companies
13    Factors Affecting Bargaining Power of Suppliers
14    Factors Affecting the Bargaining Power of Buyers
15    Factors Affecting Threat of New Entrant
16    Factors Affecting the Threat of Substitutes
17    Factors Affecting the Intensity of Competitive Rivalry
18    Global  Biologics Development Market, by Class, 2017-2027, ($Million)
19    Sales of Major Monoclonal Antibodies, 2015
20    Clinical Manufacturing Market Volume by Phase (Kilograms)
21    Clinical Manufacturing Market Value by Phase ($Million)
22    Capacity Control for Biologics
23    Manufacturing Capacity (by Company)
24    North America Biologics Drug Development Market by Facility  (Kg)
25    North America Biologics Drug Development Market by Facility  ($Million)
26    Europe Biologics Drug Development Market by Facility (Kg)
27    Europe Biologics Drug Development Market by Facility ($Million)
28    Asia Pacific Biologics Drug Development Market by Facility (Kg)
29    Asia-Pacific Biologics Drug Development Market by Facility ($Million)
30    Abbvie Inc: Overview
31    Allergan Plc: Overview
32    Amgen, Inc.: Overview
33    Boehringer Ingelheim International GmbH.: Overview
34    Catalent Inc: Overview
35    Charles River Laboratories: Overview
36    FUJIFILM Diosynth Biotechnologies: Overview
37    FUJIFILM Holdings Corporation: Overview
38    KBI Biopharma: Overview
39    Lonza: Overview
40    MabPlex Inc.: Overview
41    Patheon: Overview
42    Thermo Fisher Scientific, Inc: Overview
43    Samsung BioLogics: Overview
44    SANOFI: Overview
45    SANOFI: Product Portfolio for Global Biologics Drug Development Market
46    Singota Solutions: Overview
47    WuXi Biologics: Overview

List of Figures

1    Global Biologics Drug Development Market ($Billion)
2    Global Biologics Drug Development Market (by Class), 2017
3    Global Biologics Drug Development Market (by Class), 2027
4    Global Biologics Drug Development Market (by Facility), 2017
5    Global Biologics Drug Development Market (by Facility), 2027
6    Global Biologics Drug Development Market (by Services), 2017
7    Global Biologics Drug Development Market (by Services), 2027
8    Global Biologics Drug Development Market (by Region), 2017
9    Global Biologics Drug Development Market (by Region), 2027
10    Integrated Discovery, Development, and Commercialization of Biologics
11    Clinical Developmental Stages
12    Manufacturing Stages of Biologics
13    Stages of Drug Development Process
14    Stages of Biomanufacturing
15    Work Flow of Upstream Development and Downstream Purification
16    Stages of Formulation Development
17    Market Dynamics
18    Share of Key Developmental Strategies: January 2011 to August 2018
19    Share of Acquisitions (by Company)
20    Share of Agreements, Partnerships, Joint Ventures and Collaborations (by Company)
21    Share of Approvals (by Company)
22    Share of Clinical Study (by Company)
23    Share of Business Expansion (by Company)
24    Share of Product Launch (by Company)
25    Share of Awards (by Company)
26    Porter’s Five Forces Analysis
27    Biologics Drug Development (by Class)
28    Global mAbs Development Market,  2017-2027
29    Global Hormones Development Market, 2017-2027
30    Global Growth Factors Development Market,  2017-2027
31    Global Cytokines and Fusion Proteins Development Market, 2017-2027
32    Global Therapeutic Enzymes Development Market, 2017-2027
33    Global Blood Factors and Anticoagulants Development Market, 2017-2027
34    Global Vaccines Development Market, 2017-2027
35    Types of Facilities
36    Global Biologics Drug Development Market,(by Facility Volume) 2017-2027
37    Global Biologics Drug Development Market, (by Facility Value) 2017-2027
38    Global Biologics In-House Drug Development Market, (by Volume) 2017-2027
39    Global Biologics In-House Drug Development Market, (by Value) 2017-2027
40    Global Biologics Outsource Drug Development Market, (by Volume), 2017-2027
41    Global Biologics Outsource Drug Development Market, (by Value), 2017-2027
42    Global Biologics Pharma Excess Drug Development Market ,  (by Volume), 2017-2027
43    Global Biologics Pharma Excess Drug Development Market, (by Value), 2017-2027
44    Types of Services
45    Global Biologics Drug Development Market, (by Services), 2017-2027
46    Global Biologics Clinical Manufacturing Services Market, 2017-2027
47    Global Biologics Clinical Manufacturing Services Market, (by Drug Type Volume), 2017-2027
48    Global Biologics Clinical Manufacturing Services Market, (by Drug Type Value), 2017-2027 
49    Global Biologics Cell Bank and Cell Line Development Service Market , 2017-2027
50    Global  Biologics Cell Culture Upstream Development Market, 2017-2027
51    Global  Biologics Purification Downstream Development Market, 2017-2027
52    Concentration Of Global Biopharmaceutical Manufacturing
53    Global Biologics Formulation Development Market, 2017-2027
54    Global Biologics Bioassay Development Market, 2017-2027
55    Global Biologics Analytical Services Market, 2017-2027
56    Global Biologics Drug Development Market, (by Regional Volume) 2017-2027
57    Global Biologics Drug Development Market, (by Regional Value) 2017 -2027
58    North America Biologics Drug Development Market, (by Volume) 2017 -2027
59    North America Biologics Drug Development Market, (by Value) 2017 -2027
60    The U.S. Biologics Drug Development Market, (by Value) 2017 -2027
61    Canada Biologics Drug Development Market, (by Value) 2017 -2027
62    Europe Biologics Drug Development Market, (by Volume) 2017 -2027
63    Europe Biologics Drug Development Market, (by Value) 2017 -2027
64    The U.K. Biologics Drug Development Market, (by Value) 2017 -2027
65    Germany Biologics Drug Development Market, (by Value) 2017 -2027
66    France Biologics Drug Development Market, (by Value) 2017 -2027
67    Switzerland Biologics Drug Development Market, (by Value) 2017 -2027
68    Rest-of-Europe Biologics Drug Development Market, (by Value) 2017 -2027
69    Asia Pacific Biologics Drug Development Market, (by Volume)  2017 -2027
70    Asia Pacific Biologics Drug Development Market, (by Value) 2017 -2027
71    Japan Biologics Drug Development Market, (by Value) 2017 -2027
72    China Biologics Drug Development Market, (by Value)  2017 -2027
73    South Korea Biologics Drug Development Market, (by Value) 2017 -2027
74    India Biologics Drug Development Market, (by Value) 2017 -2027
75    Rest-of-Asia-Pacific Biologics Drug Development Marke, (by Value) 2017 -2027
76    Rest-of-the-World Biologics Drug Development Market, (by Volume) 2017 -2027
77    Rest-of-the-World Biologics Drug Development Market, (by Value) 2017 -2027
78    Contribution of Various Companies
79    AbbVie Inc.:Overall Product Portfolio
80    AbbVie Inc.: Product Portfolio for Global Biologics Drug Development Market
81    AbbVie Inc.: Overall Financials 2015-2017
82    AbbVie Inc.: Revenue (by Geography) 2015-2017
83    AbbVie Inc.: SWOT Analysis
84    Allergan Plc: Overall Product Portfolio
85    Allergan Plc: Services for Global Biologics Drug Development Market
86    Allergan Plc: Overall Financial 2015-2017
87    Allergan: Net Revenue, (by Business Segment) 2015-2017
88    Allergan Plc: SWOT Analysis
89    Amgen, Inc.: Overall Product Portfolio
90    Amgen, Inc.: Services for Global Biologics Drug Development Market
91    Amgen, Inc. : Overall Financials 2015-2017
92    Amgen, Inc. : Revenue (by Geography) 2015-2017
93    Amgen, Inc. : SWOT Analysis
94    Boehringer Ingelheim International GmbH: Overall Product Portfolio
95    Boehringer Ingelheim International GmbH: Product Portfolio for Global Biologics Drug Development Market
96    Boehringer Ingelheim International GmbH: Overall Financials 2015-2017
97    Boehringer Ingelheim International GmbH : Revenue (by Geography) 2015-2017
98    Boehringer Ingelheim International GmbH : Revenue (by Business Segment) 2015
99    Boehringer Ingelheim International GmbH: Revenue (by Business Segment) 2016-2017
100    Boehringer Ingelheim International GmbH: SWOT Analysis
101    Catalent Inc.: Overall Product Portfolio
102    Catalent Inc.: Services for Global Biologics Drug Development Market
103    Catalent, Inc.: Overall Financial 2015-2017
104    Catalent, Inc.: Net Revenue (by Business Segment) 2015-2017
105    Catalent Inc.: Net Revenue (by Region) 2015-2017
106    Catalent Inc.: SWOT Analysis
107    Charles River: Overall Product Portfolio
108    Charles River Laboratories: Services and Products for Global Biologics Drug Development Market
109    Charles River Laboratories: Overall Financial 2015-2017
110    Charles River: Net Revenue (by Business Segment) 2015-2017
111    Charles River: Net Revenue (by Region) 2015-2017
112    Charles River: SWOT Analysis
113    FUJIFILM Holdings Corporation: Overall Product Portfolio
114    FUJIFILM Diosynth Biotechnologies U.S.A., Inc. : Product Portfolio for Global Biologics Drug Development Market
115    FUJIFILM Holdings Corporation: Overall Financial 2015-2016
116    FUJIFILM Holdings Corporation: Net Revenue (by Business Segment) 2015-2016
117    FUJIFILM Holdings Corporation: Net Revenue (by Region) 2016
118    FUJIFILM Holdings Corporation- SWOT Analysis
119    KBI Biopharma: Services for Global Biologics Drug Development Market
120    KBI Biopharma.: SWOT Analysis
121    Lonza: Overall Product Portfolio
122    Lonza: Services for Global Biologics Drug Development Market
123    Lonza: Overall Financial 2015-2017
124    Lonza: Net Revenue (by Business Segment) 2015-2017
125    Lonza: Net Revenue (by Region) 2015-2016
126    Lonza: Net Revenue (by Region) 2017
127    Lonza: SWOT Analysis
128    MabPlex Inc. Solutions: Services for Global Biologics Drug Development Market
129    MabPlex Inc.: SWOT Analysis
130    Thermo Fisher Scientific Inc.: Overall Product Portfolio
131    Patheon: Product Portfolio for Global Biologics Drug Development Market
132    Thermo Fisher Scientific, Inc.: Overall Financial 2015-2017
133    Thermo Fisher Scientific, Inc.: Net Revenue (by Business Segment) 2015-2017
134    Thermo Fisher Scientific, Inc.: Net Revenue (by Region) 2015-2017
135    Thermo Fisher Scientific Inc.- SWOT Analysis
136    Samsung BioLogics: Overall Product Portfolio
137    Samsung BioLogics: Services for Global Biologics Drug Development Market
138    Samsung BioLogics: Overall Financial 2015-2017
139    Samsung BioLogics: Net Revenue (by Business Unit) 2015-2017
140    Samsung BioLogics: SWOT Analysis
141    SANOFI:  Overall Product Portfolio
142    SANOFI: Product Portfolio for Global Biologics Drug Development Market
143    Sanofi : Overall Financials 2015-2017
144    Sanofi : Revenue (by Business Segment) 2015
145    Sanofi : Revenue ( by Business Segment) 2016-2017
146    Sanofi : Revenue (by Geography) 2015
147    Sanofi : Revenue (by Geography) 2016-2017
148    SANOFI: SWOT Analysis
149    Singota Solutions: Services for Global Biologics Drug Development Market
150    Singota Solutions: SWOT Analysis
151    WuXi Biologics: Overall Product Portfolio
152    WuXi Biologics: Services for Global Biologics Drug Development Market
153    Wuxi Biologics: Overall Financial 2015-2017
154    Wuxi Biologics: Net Revenue (by Region) 2016-2017
155    WuXi Biologics: SWOT Analysis
156    Research Methodology
157    Data Triangulation
158    Key Data Points From Secondary Sources 
159    Key Data Points From Primary Sources 
160    Top-Down  Approach (Segmental Analysis)
161    Bottom-Up Approach (Segmental Analysis)
162    Assumptions and Limitations

With the increasing life expectancy and changing lifestyle of the world population, the healthcare needs across the world are changing. Physical inactivity, rising obesity, and stress along with an increase in geriatric population is expected to raise the predisposition toward the chronic diseases. The introduction of biological therapies gave a new ray of hope for people suffering from chronic diseases. The primary reason for such a shift toward biologic products is better efficacy, absence of innovator small molecule drugs, better interaction with the target as well as specificity toward targets. The entry of biosimilars makes these effective therapies more affordable, though the concern regarding their after effects still exists.

The global biologics drug development market was estimated at $2.79 billion in 2017 and is expected to grow over $8.46 billion by 2027. The introduction of targeted therapies coupled with rising adoption of patient-centric personalized medicine is expected to fuel the demand for biologics drugs in the future. Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs. The increasing biologics approval each year indicate the effectiveness of these products.

The purpose of the study is to gain a holistic view of the biologics drug development market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the biologics drug development market. The market has been segmented into ‘product class’, ‘facility’, ‘services’, and ‘geographical regions’.

Based on the product class, monoclonal antibody is anticipated to be the major contributor to the market. The next contributing segment is vaccines. However, the fastest growing segment is expected to be growth factors market.

The market can be further segmented based on facility into in-house, outsource, and PharmaExcess. The in-house manufacture of biologics is the dominant manufacturing facility as most of the biologics production and manufacture is done in-house by biopharmaceutical companies. However, PharmaExcess is expected to grow at the highest CAGR during the forecast period.

Based on services the market can be segmented into clinical manufacturing, formulation development, bioassay development, and analytical services. Clinical manufacturing is the dominant segment with the highest revenue contribution as well as the highest CAGR value for the forecast period from 2018 to 2027.

Geographically, the largest contributor to the growth of the global biologics drug development market in 2017 was North America due to the presence of pharmaceutical companies involved in R&D of biologics. North America was followed by Europe in terms of growth. However, the fastest growing region was Asia-Pacific due to the increasing presence of Contract Research Organisations (CRO).

The biologics drug development market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy, and bio-betters presents opportunities for the further growth of the biologics drug development market.

The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. The key players of the market include Abbvie, Inc., Allergan Plc, Boehringer Ingelheim International GmbH, Charles River Laboratories, Catalent Inc., Lonza Group, MabPlex Inc., Samsung Biologics, and Amgen, Inc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields
 

The pharmaceutical industry is a multibillion market consisting of innovator drugs and generics. The pharmaceutical market consists of companies involved in the research, development, manufacturing, and commercialization of drugs for human and animal use. The evolving healthcare needs across the world has led to the rise of novel medication for the treatment of various chronic diseases. Biologics is one such type of medication with proven efficacy and safety.

Biologics are defined as pharmaceutical products obtained from living cells or microorganisms. These are complex and large molecules consisting of proteins, peptides, nucleic acids, sugars, and cellular structures or a combination of these. The pharmaceutical industry is shifting toward biologic drug products due to their advantages over small molecule such as minimal toxicity and safety issues, high target specificity, and better understood mechanism of action. These factors prompt increased interest in the biologics; hence, there is a higher trend toward their discovery and development process.

The biologics drug development involves different types of services for the development of biologics as well as facility for their manufacture. The market can be segmented based on facility into in-house, outsource, and PharmaExcess. Based on services the market can be segmented into clinical manufacturing, formulation development, bioassay development, and analytical services. Based on the product class, monoclonal antibody is anticipated to be the major contributor to the market. However, the fastest growing segment is expected to be growth factors market. Geographically, the market is segmented into four regions namely, North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World.

The purpose of the study is to gain a holistic view of the biologics drug development market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of the report is centered upon conducting a detailed study of the solutions allied with the biologics drug development market. The market has been segmented into ‘product class’, ‘facility’, ‘services’, and ‘geographical regions’. The report offers the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering into the market.

This research report aims at answering various aspects of the global biologics drug discovery market with the help of key factors driving the market, threats that can possibly inhibit the overall market growth, and the current growth opportunities that is going to shape the future trajectory of the market expansion.

The answers to the following key questions can be derived from this report:

•    What are the major market drivers, challenges, and opportunities in the global biologics drug development market and their case studies?
•    What were the market shares of the leading segments and sub-segments of the global biologics drug discovery market in 2017, and what will be the shares in 2027?
•    How will each segment of the global biologics drug development market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2027?
•    What are the influencing factors that may affect the market share of the key players?
•    How will the industry evolve during the forecast period between 2017 and 2027?
•    What are the key developmental strategies implemented by the key players to stand out in this market?
•    What will be the growth rate of the PharmaExcess segment during the forecast period?
•    Who are the key outsourced manufacturers of the biologics drug development market?
•    How the market has been segmented on the basis of services? Which service is highly adopted in the biologics drug development process?
•    Which geographical location will contribute to the highest revenue generation of the biologics drug development market?

The key players of the market include Abbvie, Inc., Allergan Plc, Boehringer Ingelheim International GmbH, Charles River Laboratories, Catalent Inc., Lonza Group, MabPlex Inc., Samsung Biologics, and Amgen, Inc., among others.

   Executive Summary
   1    Market Overview
         1.1    Biologics Drug Development
         1.2    Biologics Drug Development: Key Trends
         1.3    Integrated Discovery, Development, and commercialization of Biologics
         1.4    Clinical Developmental Stages of Biologics
         1.5    Manufacturing Stages of Biologics
         1.6    Process Development
         1.7    Bio Manufacturing Process
         1.8    Formulation Development
         1.9    Biologics In-House Drug Development Market
                  1.9.1    North America
                  1.9.2    Europe
                  1.9.3    Asia-Pacific
        1.10   Biologics Outsourcing  Drug Development Market
                  1.10.1    North America
                  1.10.2    Europe
                  1.10.3    Asia-Pacific
        1.11   Biologics Drug Development Cost
 
   2    Market Dynamics
         2.1    Market Drivers
         2.2    Market Restraints
         2.3    Market Opportunities
 
   3    Competitive Landscape
         3.1    Key Developmental Strategies
                  3.1.1    Acquisitions
                  3.1.2    Agreements, Partnership, Collaboration and Joint Ventures
                  3.1.3    Approvals
                  3.1.4.   Clinical Study
                  3.1.5    Business Expansion
                  3.1.6    Product Launch
                  3.1.7    Awards
         3.2    Porter’s Five Forces Analysis
 
   4    Biologics Drug Development Market, (by Class)
         4.1    Overview
                  4.1.1    Monoclonal Antibodies (mAbs)
                  4.1.2    Hormones
                  4.1.3    Growth Factors
                  4.1.4    Cytokines and Fusion Proteins
                  4.1.5    Therapeutic Enzymes
                  4.1.6    Blood Factors and Anticoagulants
                  4.1.7    Vaccines
 
   5    Biologics Drug Development Market, (by Facility)
         5.1    Overview
                   5.1.1    In-House
                   5.1.2    Outsource
                   5.1.3    Pharma Excess
 
   6    Biologics Drug Development Market, (by Services)
         6.1    Overview
                  6.1.1    Clinical Manufacturing
                              6.1.1.1    Cell Bank Preparation and Cell Line Development
                              6.1.1.2    Cell Culture Upstream Development
                              6.1.1.3    Purification Downstream Development
                  6.1.2    Formulation Development
                  6.1.3    Bioassay Development
                  6.1.4    Analytical Services
 
   7    Biologics Drug Development Market, (by Region)
         7.1    Global Scenario
         7.2    North America
                  7.2.1    The U.S.
                  7.2.2    Canada
         7.3    Europe
                  7.3.1    The U.K.
                  7.3.2    Germany
                  7.3.3    France
                  7.3.4    Switzerland
                  7.3.5    Rest-of-Europe
         7.4    Asia Pacific
                  7.4.1    Japan
                  7.4.2    China
                  7.4.3    South Korea
                  7.4.4    India
                  7.4.5    Rest-of-Asia-Pacific
         7.5    Rest-of-the-World (RoW)
 
   8    Company Profiles
         8.1    AbbVie Inc.
                  8.1.1    Abbvie Inc. : Overview
                  8.1.2    Abbvie Inc.: Overall Product Portfolio
                              8.1.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.1.3    Financials
                              8.1.3.1    Financial Summary
                  8.1.4    SWOT Analysis
         8.2    Allergan
                  8.2.1    Allergan Plc: Overview
                  8.2.2    Allergan Plc: Overall Product Portfolio
                              8.2.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.2.3    Financials
                              8.2.3.1    Financial Summary
                  8.2.4    SWOT Analysis
         8.3    Amgen, Inc.
                  8.3.1    Amgen, Inc.: Overview
                  8.3.2    Amgen, Inc.: Overall Product Portfolio
                              8.3.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.3.3    Financials
                              8.3.3.1    Financial Summary
                  8.3.4    SWOT Analysis
         8.4    Boehringer Ingelheim International GmbH
                  8.4.1    Boehringer Ingelheim International GmbH: Overview
                  8.4.2    Boehringer Ingelheim International GmbH: Overall Product Portfolio
                              8.4.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.4.3    Financials
                              8.4.3.1    Financial Summary
                  8.4.4    SWOT Analysis
         8.5    Catalent Inc.
                  8.5.1    Catalent Inc.: Overview
                  8.5.2    Catalent Inc.: Overall Product Portfolio
                              8.5.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.5.3    Financials
                              8.5.3.1    Financial Summary
                  8.5.4    SWOT Analysis
         8.6    Charles River Laboratories
                  8.6.1    Charles River Laboratories: Overview
                  8.6.2    Charles River Laboratories: Overall Product Portfolio
                              8.6.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.6.3    Financials
                              8.6.3.1    Financial Summary
                  8.6.4    SWOT Analysis
         8.7    FUJIFILM Diosynth Biotechnologies U.S.A., Inc
                  8.7.1    FUJIFILM Diosynth Biotechnologies U.S.A., Inc: Overview
                  8.7.2    FUJIFILM Holdings Corporation: Parent Company Overview
                  8.7.3    FUJIFILM Holdings Corporation: Overall Product Portfolio
                              8.7.3.1    Product Offerings for Global Biologics Drug Development Market
                  8.7.4    Financials
                              8.7.4.1    Financial Summary
                  8.7.5    SWOT Analysis
         8.8    KBI  Biopharma
                  8.8.1    KBI Biopharma: Overview
                  8.8.2    Corporate Summary
                  8.8.3    Product Offerings for Global Biologics Drug Development Market
                  8.8.4    SWOT Analysis
         8.9    Lonza
                  8.9.1    Lonza: Overview
                  8.9.2    Lonza: Overall Product Portfolio
                              8.9.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.9.3    Financials
                              8.9.3.1    Financial Summary
                  8.9.4    SWOT Analysis
        8.10   MabPlex Inc.
                  8.10.1    MabPlex Inc.: Overview
                  8.10.2    Corporate Summary
                  8.10.3    Product Offerings for Global Biologics Drug Development Market
                  8.10.4    SWOT Analysis
        8.11   Patheon
                  8.11.1    Patheon: Overview
                  8.11.2    Thermo Fisher Scientific, Inc.: Parent Company Overview
                  8.11.3    Thermo Fisher Scientific, Inc.: Overall Product Portfolio
                                8.11.3.1    Product Offerings for Global Biologics Drug Development Market
                  8.11.4    Thermo Fisher Scientific: Financials
                                8.11.4.1    Financial Summary
                  8.11.5    SWOT Analysis
        8.12   Samsung BioLogics
                  8.12.1    Samsung BioLogics: Overview
                  8.12.2    Samsung BioLogics: Overall Product Portfolio
                                8.12.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.12.3    Financials
                                8.12.3.1    Financial Summary
                  8.12.4    SWOT Analysis
       8.13   SANOFI
                  8.13.1    SANOFI: Overview
                  8.13.2    SANOFI: Overall Product Portfolio
                                8.13.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.13.3    Financials
                                8.13.3.1    Financial Summary
                  8.13.4    SWOT Analysis
        8.14   Singota Solutions
                  8.14.1    Singota Solutions: Overview
                  8.14.2    Corporate Summary
                  8.14.3    Product Offerings for Global Biologics Drug Development Market
                  8.14.4    SWOT Analysis
        8.15   WuXi Biologics
                  8.15.1    WuXi Biologics: Overview
                  8.15.2    WuXi Biologics: Overall Product Portfolio
                                8.15.2.1    Product Offerings for Global Biologics Drug Development Market
                  8.15.3    Financials
                                8.15.3.1    Financial Summary
                  8.15.4    SWOT Analysis
 
   9    Consumer Perception(Pharmaceutical Companies) on Clinical Manufacturing of Biologics Drugs
 
   10    Report Scope and Methodology
           10.1    Scope of the Report
           10.2    Global Biologics Drug Development Market Segmentation
           10.3    Research Methodology
                      10.3.1    Data Triangulation
                      10.3.2    Key Data Points from Secondary Sources
                      10.3.3    Key Data Points from Primary Sources
                      10.3.4    Top-Down Approach (Segmental Analysis)
                      10.3.5    Bottom-Up Approach (Segmental Analysis)
           10.4    Assumptions and Limitations
           10.5    Data and Prediction Modelling
 

List of Tables

1    Total Regional Geriatric Population (by Region %), 2015 and 2030
2    Drug Approvals by FDA
3    Impact of Market Drivers
4    Impact of Market Restraints
5    Key Market Players in Biologics Drug Development
6    Biologics Drug Development Cost Per Molecule ($Million)
7    Biosimilars Drug Development Cost Per Molecule ($Million
8    Manufacturing Cost Per Gram ($/gm)
9    Global Volume Production by Company Type ($Million)
10    Impact of Market Drivers
11    Impact of Market Restraints
12    R&D Expenditure of a Few Companies
13    Factors Affecting Bargaining Power of Suppliers
14    Factors Affecting the Bargaining Power of Buyers
15    Factors Affecting Threat of New Entrant
16    Factors Affecting the Threat of Substitutes
17    Factors Affecting the Intensity of Competitive Rivalry
18    Global  Biologics Development Market, by Class, 2017-2027, ($Million)
19    Sales of Major Monoclonal Antibodies, 2015
20    Clinical Manufacturing Market Volume by Phase (Kilograms)
21    Clinical Manufacturing Market Value by Phase ($Million)
22    Capacity Control for Biologics
23    Manufacturing Capacity (by Company)
24    North America Biologics Drug Development Market by Facility  (Kg)
25    North America Biologics Drug Development Market by Facility  ($Million)
26    Europe Biologics Drug Development Market by Facility (Kg)
27    Europe Biologics Drug Development Market by Facility ($Million)
28    Asia Pacific Biologics Drug Development Market by Facility (Kg)
29    Asia-Pacific Biologics Drug Development Market by Facility ($Million)
30    Abbvie Inc: Overview
31    Allergan Plc: Overview
32    Amgen, Inc.: Overview
33    Boehringer Ingelheim International GmbH.: Overview
34    Catalent Inc: Overview
35    Charles River Laboratories: Overview
36    FUJIFILM Diosynth Biotechnologies: Overview
37    FUJIFILM Holdings Corporation: Overview
38    KBI Biopharma: Overview
39    Lonza: Overview
40    MabPlex Inc.: Overview
41    Patheon: Overview
42    Thermo Fisher Scientific, Inc: Overview
43    Samsung BioLogics: Overview
44    SANOFI: Overview
45    SANOFI: Product Portfolio for Global Biologics Drug Development Market
46    Singota Solutions: Overview
47    WuXi Biologics: Overview

List of Figures

1    Global Biologics Drug Development Market ($Billion)
2    Global Biologics Drug Development Market (by Class), 2017
3    Global Biologics Drug Development Market (by Class), 2027
4    Global Biologics Drug Development Market (by Facility), 2017
5    Global Biologics Drug Development Market (by Facility), 2027
6    Global Biologics Drug Development Market (by Services), 2017
7    Global Biologics Drug Development Market (by Services), 2027
8    Global Biologics Drug Development Market (by Region), 2017
9    Global Biologics Drug Development Market (by Region), 2027
10    Integrated Discovery, Development, and Commercialization of Biologics
11    Clinical Developmental Stages
12    Manufacturing Stages of Biologics
13    Stages of Drug Development Process
14    Stages of Biomanufacturing
15    Work Flow of Upstream Development and Downstream Purification
16    Stages of Formulation Development
17    Market Dynamics
18    Share of Key Developmental Strategies: January 2011 to August 2018
19    Share of Acquisitions (by Company)
20    Share of Agreements, Partnerships, Joint Ventures and Collaborations (by Company)
21    Share of Approvals (by Company)
22    Share of Clinical Study (by Company)
23    Share of Business Expansion (by Company)
24    Share of Product Launch (by Company)
25    Share of Awards (by Company)
26    Porter’s Five Forces Analysis
27    Biologics Drug Development (by Class)
28    Global mAbs Development Market,  2017-2027
29    Global Hormones Development Market, 2017-2027
30    Global Growth Factors Development Market,  2017-2027
31    Global Cytokines and Fusion Proteins Development Market, 2017-2027
32    Global Therapeutic Enzymes Development Market, 2017-2027
33    Global Blood Factors and Anticoagulants Development Market, 2017-2027
34    Global Vaccines Development Market, 2017-2027
35    Types of Facilities
36    Global Biologics Drug Development Market,(by Facility Volume) 2017-2027
37    Global Biologics Drug Development Market, (by Facility Value) 2017-2027
38    Global Biologics In-House Drug Development Market, (by Volume) 2017-2027
39    Global Biologics In-House Drug Development Market, (by Value) 2017-2027
40    Global Biologics Outsource Drug Development Market, (by Volume), 2017-2027
41    Global Biologics Outsource Drug Development Market, (by Value), 2017-2027
42    Global Biologics Pharma Excess Drug Development Market ,  (by Volume), 2017-2027
43    Global Biologics Pharma Excess Drug Development Market, (by Value), 2017-2027
44    Types of Services
45    Global Biologics Drug Development Market, (by Services), 2017-2027
46    Global Biologics Clinical Manufacturing Services Market, 2017-2027
47    Global Biologics Clinical Manufacturing Services Market, (by Drug Type Volume), 2017-2027
48    Global Biologics Clinical Manufacturing Services Market, (by Drug Type Value), 2017-2027 
49    Global Biologics Cell Bank and Cell Line Development Service Market , 2017-2027
50    Global  Biologics Cell Culture Upstream Development Market, 2017-2027
51    Global  Biologics Purification Downstream Development Market, 2017-2027
52    Concentration Of Global Biopharmaceutical Manufacturing
53    Global Biologics Formulation Development Market, 2017-2027
54    Global Biologics Bioassay Development Market, 2017-2027
55    Global Biologics Analytical Services Market, 2017-2027
56    Global Biologics Drug Development Market, (by Regional Volume) 2017-2027
57    Global Biologics Drug Development Market, (by Regional Value) 2017 -2027
58    North America Biologics Drug Development Market, (by Volume) 2017 -2027
59    North America Biologics Drug Development Market, (by Value) 2017 -2027
60    The U.S. Biologics Drug Development Market, (by Value) 2017 -2027
61    Canada Biologics Drug Development Market, (by Value) 2017 -2027
62    Europe Biologics Drug Development Market, (by Volume) 2017 -2027
63    Europe Biologics Drug Development Market, (by Value) 2017 -2027
64    The U.K. Biologics Drug Development Market, (by Value) 2017 -2027
65    Germany Biologics Drug Development Market, (by Value) 2017 -2027
66    France Biologics Drug Development Market, (by Value) 2017 -2027
67    Switzerland Biologics Drug Development Market, (by Value) 2017 -2027
68    Rest-of-Europe Biologics Drug Development Market, (by Value) 2017 -2027
69    Asia Pacific Biologics Drug Development Market, (by Volume)  2017 -2027
70    Asia Pacific Biologics Drug Development Market, (by Value) 2017 -2027
71    Japan Biologics Drug Development Market, (by Value) 2017 -2027
72    China Biologics Drug Development Market, (by Value)  2017 -2027
73    South Korea Biologics Drug Development Market, (by Value) 2017 -2027
74    India Biologics Drug Development Market, (by Value) 2017 -2027
75    Rest-of-Asia-Pacific Biologics Drug Development Marke, (by Value) 2017 -2027
76    Rest-of-the-World Biologics Drug Development Market, (by Volume) 2017 -2027
77    Rest-of-the-World Biologics Drug Development Market, (by Value) 2017 -2027
78    Contribution of Various Companies
79    AbbVie Inc.:Overall Product Portfolio
80    AbbVie Inc.: Product Portfolio for Global Biologics Drug Development Market
81    AbbVie Inc.: Overall Financials 2015-2017
82    AbbVie Inc.: Revenue (by Geography) 2015-2017
83    AbbVie Inc.: SWOT Analysis
84    Allergan Plc: Overall Product Portfolio
85    Allergan Plc: Services for Global Biologics Drug Development Market
86    Allergan Plc: Overall Financial 2015-2017
87    Allergan: Net Revenue, (by Business Segment) 2015-2017
88    Allergan Plc: SWOT Analysis
89    Amgen, Inc.: Overall Product Portfolio
90    Amgen, Inc.: Services for Global Biologics Drug Development Market
91    Amgen, Inc. : Overall Financials 2015-2017
92    Amgen, Inc. : Revenue (by Geography) 2015-2017
93    Amgen, Inc. : SWOT Analysis
94    Boehringer Ingelheim International GmbH: Overall Product Portfolio
95    Boehringer Ingelheim International GmbH: Product Portfolio for Global Biologics Drug Development Market
96    Boehringer Ingelheim International GmbH: Overall Financials 2015-2017
97    Boehringer Ingelheim International GmbH : Revenue (by Geography) 2015-2017
98    Boehringer Ingelheim International GmbH : Revenue (by Business Segment) 2015
99    Boehringer Ingelheim International GmbH: Revenue (by Business Segment) 2016-2017
100    Boehringer Ingelheim International GmbH: SWOT Analysis
101    Catalent Inc.: Overall Product Portfolio
102    Catalent Inc.: Services for Global Biologics Drug Development Market
103    Catalent, Inc.: Overall Financial 2015-2017
104    Catalent, Inc.: Net Revenue (by Business Segment) 2015-2017
105    Catalent Inc.: Net Revenue (by Region) 2015-2017
106    Catalent Inc.: SWOT Analysis
107    Charles River: Overall Product Portfolio
108    Charles River Laboratories: Services and Products for Global Biologics Drug Development Market
109    Charles River Laboratories: Overall Financial 2015-2017
110    Charles River: Net Revenue (by Business Segment) 2015-2017
111    Charles River: Net Revenue (by Region) 2015-2017
112    Charles River: SWOT Analysis
113    FUJIFILM Holdings Corporation: Overall Product Portfolio
114    FUJIFILM Diosynth Biotechnologies U.S.A., Inc. : Product Portfolio for Global Biologics Drug Development Market
115    FUJIFILM Holdings Corporation: Overall Financial 2015-2016
116    FUJIFILM Holdings Corporation: Net Revenue (by Business Segment) 2015-2016
117    FUJIFILM Holdings Corporation: Net Revenue (by Region) 2016
118    FUJIFILM Holdings Corporation- SWOT Analysis
119    KBI Biopharma: Services for Global Biologics Drug Development Market
120    KBI Biopharma.: SWOT Analysis
121    Lonza: Overall Product Portfolio
122    Lonza: Services for Global Biologics Drug Development Market
123    Lonza: Overall Financial 2015-2017
124    Lonza: Net Revenue (by Business Segment) 2015-2017
125    Lonza: Net Revenue (by Region) 2015-2016
126    Lonza: Net Revenue (by Region) 2017
127    Lonza: SWOT Analysis
128    MabPlex Inc. Solutions: Services for Global Biologics Drug Development Market
129    MabPlex Inc.: SWOT Analysis
130    Thermo Fisher Scientific Inc.: Overall Product Portfolio
131    Patheon: Product Portfolio for Global Biologics Drug Development Market
132    Thermo Fisher Scientific, Inc.: Overall Financial 2015-2017
133    Thermo Fisher Scientific, Inc.: Net Revenue (by Business Segment) 2015-2017
134    Thermo Fisher Scientific, Inc.: Net Revenue (by Region) 2015-2017
135    Thermo Fisher Scientific Inc.- SWOT Analysis
136    Samsung BioLogics: Overall Product Portfolio
137    Samsung BioLogics: Services for Global Biologics Drug Development Market
138    Samsung BioLogics: Overall Financial 2015-2017
139    Samsung BioLogics: Net Revenue (by Business Unit) 2015-2017
140    Samsung BioLogics: SWOT Analysis
141    SANOFI:  Overall Product Portfolio
142    SANOFI: Product Portfolio for Global Biologics Drug Development Market
143    Sanofi : Overall Financials 2015-2017
144    Sanofi : Revenue (by Business Segment) 2015
145    Sanofi : Revenue ( by Business Segment) 2016-2017
146    Sanofi : Revenue (by Geography) 2015
147    Sanofi : Revenue (by Geography) 2016-2017
148    SANOFI: SWOT Analysis
149    Singota Solutions: Services for Global Biologics Drug Development Market
150    Singota Solutions: SWOT Analysis
151    WuXi Biologics: Overall Product Portfolio
152    WuXi Biologics: Services for Global Biologics Drug Development Market
153    Wuxi Biologics: Overall Financial 2015-2017
154    Wuxi Biologics: Net Revenue (by Region) 2016-2017
155    WuXi Biologics: SWOT Analysis
156    Research Methodology
157    Data Triangulation
158    Key Data Points From Secondary Sources 
159    Key Data Points From Primary Sources 
160    Top-Down  Approach (Segmental Analysis)
161    Bottom-Up Approach (Segmental Analysis)
162    Assumptions and Limitations

With the increasing life expectancy and changing lifestyle of the world population, the healthcare needs across the world are changing. Physical inactivity, rising obesity, and stress along with an increase in geriatric population is expected to raise the predisposition toward the chronic diseases. The introduction of biological therapies gave a new ray of hope for people suffering from chronic diseases. The primary reason for such a shift toward biologic products is better efficacy, absence of innovator small molecule drugs, better interaction with the target as well as specificity toward targets. The entry of biosimilars makes these effective therapies more affordable, though the concern regarding their after effects still exists.

The global biologics drug development market was estimated at $2.79 billion in 2017 and is expected to grow over $8.46 billion by 2027. The introduction of targeted therapies coupled with rising adoption of patient-centric personalized medicine is expected to fuel the demand for biologics drugs in the future. Moreover, ever-increasing understanding of the cell physiology and stress, as well as the factors involved in protein production and heterologous gene expression have empowered the use of different living factories in the development of novel therapeutic biologic drugs. The increasing biologics approval each year indicate the effectiveness of these products.

The purpose of the study is to gain a holistic view of the biologics drug development market in terms of various factors influencing it such as recent trends, technological advancements, and regulatory aspects of the market. The scope of this report is centered upon conducting a detailed study of the solutions allied with the biologics drug development market. The market has been segmented into ‘product class’, ‘facility’, ‘services’, and ‘geographical regions’.

Based on the product class, monoclonal antibody is anticipated to be the major contributor to the market. The next contributing segment is vaccines. However, the fastest growing segment is expected to be growth factors market.

The market can be further segmented based on facility into in-house, outsource, and PharmaExcess. The in-house manufacture of biologics is the dominant manufacturing facility as most of the biologics production and manufacture is done in-house by biopharmaceutical companies. However, PharmaExcess is expected to grow at the highest CAGR during the forecast period.

Based on services the market can be segmented into clinical manufacturing, formulation development, bioassay development, and analytical services. Clinical manufacturing is the dominant segment with the highest revenue contribution as well as the highest CAGR value for the forecast period from 2018 to 2027.

Geographically, the largest contributor to the growth of the global biologics drug development market in 2017 was North America due to the presence of pharmaceutical companies involved in R&D of biologics. North America was followed by Europe in terms of growth. However, the fastest growing region was Asia-Pacific due to the increasing presence of Contract Research Organisations (CRO).

The biologics drug development market presents with opportunities to change the treatment options. The development of antibody drug conjugates, glycosylated antibodies, Chimeric Antigen Receptor-T (CAR-T) cell therapy, and bio-betters presents opportunities for the further growth of the biologics drug development market.

The report provides in-depth SWOT analysis of different key players of the market, supported by extensive financial summary of each. The key players of the market include Abbvie, Inc., Allergan Plc, Boehringer Ingelheim International GmbH, Charles River Laboratories, Catalent Inc., Lonza Group, MabPlex Inc., Samsung Biologics, and Amgen, Inc., among others.

We understand that your business need specific answers pertaining to the market. And , therefore, we do provide customised research tailored to your need.

With the purchase of this report, you are entitled to certain degree of free customisation within the scope of the study.

Do get in touch to help us understand how we can serve u better with a custom solution to your research needs. We assure quick turnaround for your pressing business requirements.

Contact Information


Name *
Email *
 
Company Name *
Designation
 
 
Contact No. *
Other Details
 
 

Write the characters in the image above
 
 
* Required Fields


related reports



Get yourself updated on key emerging technology markets

Know about our market intelligence coverage in key sectors